ABSTRACT
Background Apraxia represents a core feature of Alzheimer’s disease, a neurodegenerative disorder associated with increased β-amyloid plaques and tau deposition. However, descriptions of apraxic deficits in AD patients are still scarce. Here, we comprehensively investigate apraxia profiles and their impact on general cognitive deficits in patients with biomarker-verified Alzheimer’s pathology.
Methods We characterized the frequency and patterns of apraxic deficits in patients with biomarker-verified Alzheimer’s pathology (n=45) using a battery of standardized apraxia tests. Demographic variables and apraxia scores were related to patients’ general cognitive impairment using hierarchical regression analyses.
Results Apraxic deficits were found in 78% of patients with biomarker-verified Alzheimer’s pathology. AD patients were more impaired in imitating finger gestures (than hand gestures: 76.6% vs. 87.8%, p < 0.001), and imitating complex hand movements (than single hand movements: 76.3% vs. 96.7%, p < 0.001), even when controlling for general cognitive impairment. Apraxia assessments explained about 60% of the variance related to the severity of general cognitive deficits, with deficits in pantomiming object use (beta coefficient: 0.55, p = 0.017) and imitating finger gestures (beta coefficient: −0.51, p < 0.001) being significant predictors of general cognitive impairment.
Conclusions These findings underline the relevance of apraxia in patients with biomarker-verified Alzheimer’s pathology. Data revealed distinct apraxia profiles independent of patients’ general cognitive status and showed that praxis performance, especially apraxic deficits in pantomiming the use of objects and imitating finger gestures, predicts general cognitive functioning in Alzheimer’s disease.
What is already known on this topic Apraxic deficits have been commonly reported in patients with suspected Alzheimer’s disease (AD). Current diagnostic criteria of AD include disease-specific biomarkers (i.e., amyloid and tau) reflecting the neuropathological changes in AD. However, little is known about the prevalence and characteristics of apraxia in patients with biomarker-verified Alzheimer’s pathology.
What this study adds In a well-defined sample of patients with evidence of Alzheimer’s pathology based on positive amyloid and tau biomarkers in cerebrospinal fluid (CSF) or positron emission tomography (PET), apraxic deficits are common, show differential patterns even after controlling for general cognitive deficits, and account for variance in the severity of the patients’ general cognitive impairment.
How this study might affect research, practice or policy This study shows that in patients with biomarker-verified Alzheimer’s pathology apraxic deficits are a relevant symptom that can predict general cognitive performance in mild to moderate disease stages.
Our results warrant further investigation into the neuropathology underlying apraxic deficits in Alzheimer’s disease by examining the relationship between apraxic deficits and regional amyloid and tau deposition in the brain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 431549029 - SFB 1451. GRF gratefully acknowledges support from the Marga and Walter Boll-Stiftung. Open access publication funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - 491111487
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of the Medical Faculty of the University of Cologne.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Data are available from the corresponding author upon reasonable request.